Loading organizations...
Ackermans & van Haaren operates as a diversified investment company, focusing on long-term value creation across multiple sectors. Core activities span marine engineering and contracting, private banking, real estate development, and energy & resources. This strategic breadth allows the company to support businesses through a robust, multi-faceted investment approach, cultivating a portfolio of strong, independent enterprises.
Established in Antwerp in 1876, the firm was founded by Jules Ackermans and Henri van Haaren. Their insight addressed expanding demands of Belgian ports, identifying a critical need for civil works and dredging. Leveraging mechanization, they strategically positioned their enterprise to enhance North Sea gateways' efficiency, laying the groundwork for a long-standing, diversified group.
Ackermans & van Haaren primarily serves as a strategic partner and investor for its diverse portfolio companies, fostering development. Its vision centers on generating enduring shareholder value and promoting sustainable growth through a disciplined, long-term investment philosophy. The company aims to cultivate robust, independent businesses, maintaining a forward-looking perspective on market trends and opportunities.
Key people at Ackermans & van Haaren.
Key people at Ackermans & van Haaren.
Ackermans & van Haaren has 5 tracked investments across 5 companies. The latest tracked deal is $55.1M Other Equity in Medikabazaar in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 19, 2026 | Medikabazaar | $55.1M Other Equity | — | British International Investment, Creaegis, Healthquad, Rebright Partners |
| Sep 4, 2025 | MRM Health | $64.1M Series B | Jean Patrick Hennebelle | RAF Moons, Goedele Ertveldt, Julian Zachmann, OMX Ventures, Qbic II |
| Jul 1, 2024 | Confo Therapeutics | $65.0M Series B | Ackermans & VAN Haaren | BGV (biogeneration Ventures) |
| Aug 25, 2022 | AstriVax | $29.9M Seed | Caroline Goddeeris, Shelley Margetson | BNP Paribas Fortis Private Equity, Flanders Future Tech Fund, KU Leuven, Merieux Equity Partners, Thuja Capital |
| Jul 27, 2020 | Indigo Diabetes | $44.4M Series B | JAN VAN DEN Bossche | Capricorn Venture Partners, Imec.xpand, Qbicii, Titan Baratto |